Protocols for anticoagulation management in pediatric extracorporeal membrane oxygenation: A comparative retrospective study
Open Access
- 21 January 2026
- journal article
- Published by SAGE Publications in Perfusion
- Vol. 41 (7) , 1251-1259
Abstract
Introduction: In children undergoing Extracorporeal Membrane Oxygenation (ECMO), anticoagulation is given to counterbalance the risk of thrombosis. Several laboratory tests are available to monitor heparin, but the ideal method still needs to be determined. Methods: This retrospective cohort study included all patients under 18 years on ECMO support between 2010 and 2021. At our institution, the test used to monitor unfractionated heparin changed over time, dividing patients into three periods, using either activated clotting time (ACT) (2010-2014), activated partial thromboplastin time (aPTT) (2014-2018) or anti-Xa (2018-2021). The primary objective was to compare the occurrence of hemorrhagic complications. Secondary objectives included thrombotic complications, neurological complications, and survival. Results: We included 118 ECMO runs of which 30 ACT-guided, 40 aPTT-guided, and 48 anti-Xa-guided. No statistically significant differences were found in hemorrhagic complications [respectively 46.7% vs. 52.5% vs. 60.4%; p = 0.48], thrombotic complications ( p = 0.15), neurological complications ( p = 0.13), or 30-days survival ( p = 0.84). Duration of ECMO and length of hospital stay were both the shortest in the anti-Xa-guided group (respectively p = 0.02; p = 0.02). During ECMO, the anti-Xa-guided group received a higher unfractionated heparin dose compared to the aPTT- and ACT-guided group [respectively 839 [651–981] vs. 543 [407–692] vs. 330 [223–489] IU/kg d -1 , p < 0.001]. Conclusion: In our study, the test or titration method used to guide heparin-dosing in children on ECMO, was not associated with hemorrhagic complications and death. Of note, the dose of unfractionated heparin was significantly higher in the anti-Xa-guided group. Combined testing may be more effective than a single method, more studies are needed to establish the optimal strategy.Keywords
This publication has 19 references indexed in Scilit:
- Extracorporeal Life Support Organization Registry International Report 2022: 100,000 SurvivorsASAIO Journal, 2024
- 2021 ELSO Adult and Pediatric Anticoagulation GuidelinesASAIO Journal, 2022
- Antifactor Xa Monitoring and Hematologic Complications of Pediatric Extracorporeal Membrane OxygenationASAIO Journal, 2020
- Correlation Among Antifactor Xa, Activated Partial Thromboplastin Time, and Heparin Dose and Association with Pediatric Extracorporeal Membrane Oxygenation ComplicationsASAIO Journal, 2020
- Anti-Factor Xa–Based Anticoagulation during Extracorporeal Membrane Oxygenation: Potential Problems and Possible SolutionsSeminars in Thrombosis and Hemostasis, 2019
- Routine laboratory measures of heparin anticoagulation for children on extracorporeal membrane oxygenation: Systematic review and meta-analysisThrombosis Research, 2019
- Anticoagulation in neonatal ECMOSeminars in Perinatology, 2018
- Anti-Xa Directed Protocol for Anticoagulation Management in Children Supported With Extracorporeal Membrane OxygenationASAIO Journal, 2015
- Assessing Heparin Dosing in Neonates on Venoarterial Extracorporeal Membrane OxygenationASAIO Journal, 2007
- Coagulation factor activity during neonatal extra-corporeal membrane oxygenationIntensive Care Medicine, 2001